Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC25H25F6N7O3S |
InChIKeyTUIBXAWZSUTTQP-UUVZNBFESA-N |
CAS Registry3068345-70-7 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | Belgium | 05 May 2025 |





